Xdynia's Angel Round

Xdynia raised a round of funding on March 29, 2013.

Xdynia is developing a class of compounds targeting the Cav 3.2 Ca++ channel, a common pathway in the development of neuropathic pain. These inhibitors are designed to alleviate common side-effects re…

Articles about Xdynia's Angel Round: